Swiss-based Novartis recently announced the discontinuation of the CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients based on the interim analysis from the study. The investigators have found that the investigational product is less efficacious as compared to tacrolimus-based treatment (e.g. Prograf) in the prevention of organ rejection in patients receiving a kidney transplant. In the study, both the investigational Novartis drug and tacrolimus were used in combination with other immunosuppressive therapies such as induction therapy, mycophenolate, and corticosteroids.
Novartis will continue to study CFZ533 in liver transplants as well as in other studies of other conditions, such as hidradenitis suppurativa and Sjogren’s syndrome. Additionally, Novartis will continue to review CIRRUS-1 study data, and disclosed the company will share with the broader scientific community.
The Study Drug
Iscalimab is a new, fully human, monoclonal antibody preventing cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types. In a recent multicenter, randomized control trial (NCT02217410), with the primary endpoint of non-inferiori...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).